## **Product** Data Sheet

## JAK-IN-19

Molecular Formula:

**Cat. No.:** HY-144075

Molecular Weight: 469.59

Target: JAK

Pathway: Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

 $\mathsf{C}_{26}\mathsf{H}_{36}\mathsf{FN}_5\mathsf{O}_2$ 

## **BIOLOGICAL ACTIVITY**

Description

JAK-IN-19 is a potent JAK inhibitor (PBMC IFN $\gamma$  pIC $_{50}$ =7.2 and HLF Eotaxin pIC $_{50}$ =7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC $_{50}$ =7.0, Aurora B pIC $_{50}$ =5.8)<sup>[1]</sup>.

## **REFERENCES**

[1]. Wellaway CR, et al. Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism. J Med Chem. 2022 Jan 13;65(1):633-664.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA